Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
Part of paid clinical trials in Little Rock, Arkansas.
- Sponsor
- University of Arkansas
- Study ID
- NCT01530373
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- solifenacin — DRUGoral solifenacin 5.0 mg daily for 3 weeks
- Clonidine — DRUGoral clonidine 0.1 mg daily for 3 weeks
Study Details
Hot flashes present a considerable problem for many breast cancer patients; these symptoms may be intensified by hormonal therapies, such as aromatase inhibitors or tamoxifen. This study examines the value of solifenacin (a muscarinic acetylcholine receptor antagonist) in reducing hot flashes, compared with clonidine (a medication often used for treating hot flashes).
Key Dates
- First listed
- Feb 9, 2012
- Start date
- Feb 29, 2012
- Status verified
- Mar 2026
- Primary completion
- Jul 31, 2027
- Completion
- Sep 30, 2028
Study Design
- Enrollment
- 110 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: solifenacinoral solifenacin 5.0 mg daily for 3 weeks
- Active Comparator: clonidineoral clonidine 0.1 mg daily for 3 weeks
Primary Outcome Measure
Efficacy: hot flash composite and frequency scores (daily diary) [ Time Frame: from baseline to end of treatment (3 weeks) ]
Central Contacts
- Allen C Sherman, PhD501-686-8700
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences | Little Rock | Arkansas | 722205 | Issam Makhoul, MD (SUB_INVESTIGATOR) Ronda Henry-Tillman, MD (SUB_INVESTIGATOR) |
Find similar trials in Little Rock, AR
By condition
By specialty
Related Studies
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25PHASE3 · Recruiting · NRG Oncology · Anchorage, Alaska
- Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer SurvivorsRecruiting · NRG Oncology · Anchorage, Alaska
- A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)PHASE3 · Recruiting · AstraZeneca · Daphne, Alabama